SEC Form 3 · accession 0000899243-17-010249
PROVECTUS BIOPHARMACEUTICALS, INC. · PVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Horowitz
Director
Period of report
Apr 3, 2017
Accepted (ET)
Apr 13, 2017 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000315545
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,392,243 | D | ||
| Common Stock | holding | — | — | — | 50,000 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Warrants (right to buy)F1 | $1.00 | holding | — | — | — | — | Oct 23, 2018 | Common Stock | 100,000 | — | D |
| Common Stock Warrants (right to buy)F1 | $2.00 | holding | — | — | — | — | Dec 31, 2018 | Common Stock | 100,000 | — | D |
| Common Stock Warrants (right to buy)F1 | $1.00 | holding | — | — | — | — | Dec 31, 2018 | Common Stock | 400,000 | — | D |
| Common Stock Warrants (right to buy)F1 | $0.85 | holding | — | — | — | — | Jun 19, 2020 | Common Stock | 400,000 | — | D |
Explanation of responses
- F1The common stock warrants are exercisable currently.